EP4127136A4 - Verwendung von exosomenbasierter freisetzung von nf-kb-inhibitoren - Google Patents

Verwendung von exosomenbasierter freisetzung von nf-kb-inhibitoren Download PDF

Info

Publication number
EP4127136A4
EP4127136A4 EP21781109.0A EP21781109A EP4127136A4 EP 4127136 A4 EP4127136 A4 EP 4127136A4 EP 21781109 A EP21781109 A EP 21781109A EP 4127136 A4 EP4127136 A4 EP 4127136A4
Authority
EP
European Patent Office
Prior art keywords
exosome
inhibitors
based delivery
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21781109.0A
Other languages
English (en)
French (fr)
Other versions
EP4127136A1 (de
Inventor
Chulhee Choi
Kyungsun CHOI
Jae-Kwang YOO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ilias Biologics Inc
Original Assignee
Ilias Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilias Biologics Inc filed Critical Ilias Biologics Inc
Publication of EP4127136A1 publication Critical patent/EP4127136A1/de
Publication of EP4127136A4 publication Critical patent/EP4127136A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP21781109.0A 2020-03-31 2021-03-31 Verwendung von exosomenbasierter freisetzung von nf-kb-inhibitoren Pending EP4127136A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20200039011 2020-03-31
US202063112154P 2020-11-10 2020-11-10
US202063112155P 2020-11-11 2020-11-11
PCT/IB2021/052708 WO2021198961A1 (en) 2020-03-31 2021-03-31 Use of exosome-based delivery of nf-kb inhibitors

Publications (2)

Publication Number Publication Date
EP4127136A1 EP4127136A1 (de) 2023-02-08
EP4127136A4 true EP4127136A4 (de) 2024-04-03

Family

ID=77928093

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21781109.0A Pending EP4127136A4 (de) 2020-03-31 2021-03-31 Verwendung von exosomenbasierter freisetzung von nf-kb-inhibitoren

Country Status (7)

Country Link
EP (1) EP4127136A4 (de)
JP (1) JP7498293B2 (de)
KR (2) KR20210124180A (de)
CN (1) CN115335079A (de)
AU (1) AU2021247253A1 (de)
CA (1) CA3173845A1 (de)
WO (1) WO2021198961A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115212234B (zh) * 2021-10-22 2023-11-10 武汉大学中南医院 纤维网状细胞来源的外泌体在制备用于治疗和/或预防脓毒症急性肾损伤的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018062973A1 (en) * 2016-09-30 2018-04-05 Cellex Life Sciences, Incorporated Compositions containing protein loaded exosome and methods for preparing and delivering the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2662326T5 (es) * 2013-04-12 2021-08-04 Evox Therapeutics Ltd Vesículas de suministro terapéutico
KR101877010B1 (ko) * 2016-09-30 2018-08-09 한국과학기술원 super-repressor-IκB 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
EP4035659A1 (de) * 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosome zur ausgabe von therapeutischen wirkstoffen
CN107158390A (zh) * 2017-07-12 2017-09-15 上海市东方医院 组蛋白去乙酰化酶hdac6的抑制剂在制备防治急性肾损伤药物中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018062973A1 (en) * 2016-09-30 2018-04-05 Cellex Life Sciences, Incorporated Compositions containing protein loaded exosome and methods for preparing and delivering the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABULIZI PALIDA ET AL: "Growth Differentiation Factor-15 Deficiency Augments Inflammatory Response and Exacerbates Septic Heart and Renal Injury Induced by Lipopolysaccharide", SCIENTIFIC REPORTS, vol. 7, no. 1, 21 April 2017 (2017-04-21), XP055845343, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-017-00902-5.pdf> DOI: 10.1038/s41598-017-00902-5 *
LI LONG ET AL: "Exosomes Derived From Mesenchymal Stem Cells Ameliorate Renal Ischemic-Reperfusion Injury Through Inhibiting Inflammation and Cell Apoptosis", FRONTIERS IN MEDICINE, vol. 6, 19 November 2019 (2019-11-19), FR, XP093134229, ISSN: 2296-858X, DOI: 10.3389/fmed.2019.00269 *
MAKRIS KONSTANTINOS ET AL: "Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes", CLINICAL BIOCHEMIST REVIEWS, 1 May 2016 (2016-05-01), Australia, pages 85 - 98, XP093134310, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198510/pdf/cbr-37-85.pdf> [retrieved on 20240223] *
See also references of WO2021198961A1 *

Also Published As

Publication number Publication date
KR20210124180A (ko) 2021-10-14
CN115335079A (zh) 2022-11-11
CA3173845A1 (en) 2021-10-07
JP7498293B2 (ja) 2024-06-11
EP4127136A1 (de) 2023-02-08
JP2023519700A (ja) 2023-05-12
WO2021198961A1 (en) 2021-10-07
AU2021247253A1 (en) 2022-10-20
KR20220149781A (ko) 2022-11-08

Similar Documents

Publication Publication Date Title
EP4135712A4 (de) Transdermale mikrodosierung von psychedelikaderivaten
EP4125902A4 (de) Transdermale verabreichung von dextromethorphan
EP4143196A4 (de) Pi3k-a-hemmer und verfahren zur verwendung davon
EP4069212A4 (de) Inhibitoren von hif-2alpha
EP3813853A4 (de) Zusammensetzungen zur wirkstofffreisetzung und verfahren zu deren verwendung
EP3962479A4 (de) Kcnt1-inhibitoren und verfahren zur verwendung
EP3962481A4 (de) Kcnt1-hemmer und verfahren zur verwendung
EP4149552A4 (de) Zusammensetzungen und verfahren zur erhöhung der wirksamkeit eines arzneimittels
EP3735242A4 (de) Metallo-beta-lactamase-inhibitoren und verfahren zu deren verwendung
EP3982949A4 (de) Inhibitoren von sarm1
EP3983386A4 (de) Acss2-hemmer und verfahren zur verwendung
EP4045024A4 (de) Transdermale verabreichung von cannabidiol
EP4125831A4 (de) Kcnt1-inhibitoren und verfahren zur verwendung
EP4003499A4 (de) Systeme und verfahren zur anhaltenden linderung von chronischen schmerzen
EP3980011A4 (de) Inhibitoren von sarm1
EP3986894A4 (de) Ektonukleotidasehemmer und verfahren zur verwendung davon
EP4058015A4 (de) Allosterische egfr-inhibitoren und verfahren zur verwendung davon
EP4098258A4 (de) Pharmazeutische verwendung einer verbindung auf ketoamidbasis
EP4127136A4 (de) Verwendung von exosomenbasierter freisetzung von nf-kb-inhibitoren
EP3959197A4 (de) Papd5-inhibitoren und verfahren zur verwendung davon
EP4110317A4 (de) Kcnt1-inhibitoren und verfahren zur verwendung
EP3976048A4 (de) Pharmazeutische formulierungen und systeme zur abgabe eines androgenen wirkstoffs und eines aromatase-inhibitors und verfahren zur verwendung
EP3947351A4 (de) Kleinmolekulare parg-inhibitoren und verfahren zu deren verwendung
EP3972601A4 (de) Nanopartikelformulierung eines bcl-2-inhibitors
EP3986407A4 (de) Allosterische egfr-inhibitoren und verfahren zur verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221011

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C12N0005071000

Ipc: A61K0035120000

A4 Supplementary search report drawn up and despatched

Effective date: 20240305

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/17 20060101ALI20240228BHEP

Ipc: A61P 29/00 20060101ALI20240228BHEP

Ipc: C07K 14/47 20060101ALI20240228BHEP

Ipc: C12N 5/073 20100101ALI20240228BHEP

Ipc: C12N 5/071 20100101ALI20240228BHEP

Ipc: A61K 35/12 20150101AFI20240228BHEP